Кравчук Юрий Алексеевич

Bio: Кравчук Юрий Алексеевич is an academic researcher. The author has contributed to research in topics: Systemic inflammation & Dysbiosis. The author has an hindex of 1, co-authored 2 publications receiving 3 citations.

Disease as a result of violations of the symbiotic relationship between the host and the microbiota with pathogens

Abstract: Recent achievements in many sciences have led to an understanding of the need to form new ideas about the nature of human relationships with the environment and the inner world, his health, the principles of disease formation and their prevention. There has been a transition from a collection of achievements of various sciences to a holistic paradigm that unites a person as an organism and as a person, his inner and surrounding world. It became obvious that this could not be done within the framework of the previous general theories of medicine. To this end, the authors propose a new theory of medicine: "the theory of noospheric-anthropogenic harmony". From the standpoint of this theory, the mechanisms of the relationship of microbiota and pathogens with the protective and acceptive immunity of a healthy and sick person, as well as the mechanisms of microbiota regulation, are considered. The paradigm of dysbiosis as the cause of many diseases and main homeostatic mechanisms that provide symbiotic relationships of microbiota, immunity and its role in the mechanisms of natural tolerance and formation of various disease, such as, autoimmune ones and tumors, require a change in the acceptedtreatment and prevention. A new approach should be based on using a new class of drugs — metabiotics, which in their term influence microbiota.

Diseases of the digestive organs and covid-19

Abstract: With a new coronavirus infection (COVID-19), gastroenterological symptoms are often detected, which is due to both the damage to the digestive organs by the SARS-CoV-2 coronavirus and the exacerbation of chronic diseases, as well as aggressive multicomponent therapy. The severity of gastroenterological manifestations, primarily impaired liver function, is associated with a more severe and complicated course of COVID-19 infection. Numerous mechanisms of damage to the digestive organs in COVID-19 have been identified: direct damage by the virus due to resuscitation and multicomponent therapy, impaired central and peripheral nervous regulation, immunothrombotic syndrome, virus persistence in the gastrointestinal tract, induction of autoimmune reactions by the virus, humoral disorders (changes in serotonin levels, bradykinin, activation of mast cells). Violation of the microbial-tissue complex of the intestine and the permeability of the intestinal barrier, induced by the SARS-CoV-2 virus, ensures the formation and progression of chronic systemic inflammation, cytokine aggression, insulin resistance, endothelial dysfunction, which affect the severity of the infection. Therapy for patients with COVID-19 should include therapeutic approaches aimed at correcting disorders of the intestinal microbiota, intestinal barrier permeability, and relief of gastroenterological manifestations

Функциональное питание и его перспективы как способ пищевой коррекции остеопороза

Abstract: Рассматриваются актуальные вопросы заболеваемости остеопорозом и способы его пищевой коррекции. Показана возможность функционального питания при остеопорозе и в связи с этим необходимость расширения ассортимента функциональных пищевых продуктов, богатых кальцием и витамином Д.

Метабиотики - новая технология профилактики и лечения заболеваний, связанных с микроэкологическими нарушениями в организме человека

Abstract: The human symbiotic microbiota produces various bio-active molecules having chemical and functional similarity to dietary nutrients and /or endogenous compounds. Various factors and agents cause the imbalance of host/microbial dialogue. Currently for conservation and restoration of human microbial community various probiotics and prebiotics are used. Unfortunately, probiotic effects are often short term or absent or uncertain; traditional probiotics may also have non-desirable side effects in the application. For these reasons, the search for microbial molecule modifiers of host/microbe axis is emerging, especially with regard to personal medicine. These compounds have been named metabiotics (M). M are structural components of known probiotic microorganisms and/or their metabolites and/or signaling molecules that can restoring shortages and disruption of the balance of mitochondrial, microbial or cellular LMW substances with increased health effectiveness. They have some advantages (certain chemical structure, well dosed, safety, long shelf-life) in optimizing host gene expression, epigenetic, energetic, metabolic, immune, informational, regulatory, transport, neuro-hormonal and/or behavioral responses associated with the symbiotic microbiota. M can act as independent means or as enriching additives in functional foods. Simple microbial molecules can also be used in constructing hybrid M containing multiple metabolites and structural components separately or in combination with herbal compounds. Special attention should be paid to the design of M with specific targets in the host. Further investigations will clarify what natural microbial or artificial (semi-synthetic, synthetic, hybolite) pan- or selective M may affect host functions, biochemical and signal processes.

Irritable bowel syndrome: current aspects of etiology, pathogenesis, clinic and treatment: A review

Abstract: Among functional gastrointestinal disorders, Irritable bowel syndrome (IBS) rightfully continues to maintain its leading position. IBS is a kind of standard for understanding the pathogenetic essence of functional diseases of the digestive system, since it is the most common, studied and studied pathology. So, for the query "Irritable Bowel Syndrome" in the electronic database PubMed as of July 30, 2022, 16 599 sources were found, and for the query "Irritable Bowel Syndrome" in the scientific electronic library eLIBRARY.RU 6316. The first part of the review deals with topical aspects of the etiology, pathogenesis and clinical presentation of IBS. The urgency of the problem of IBS is associated with a significant decrease in the quality of life of patients. The review focuses on the role of psycho-emotional disorders, changes localized at the level of the intestinal wall; and a new coronavirus infection COVID-19 in the development of IBS. Abdominal pain as the leading manifestation of IBS is associated primarily with spasm. In this context, antispasmodic drugs can be considered not only as symptomatic agents, but also as pathogenetic therapy for IBS. In the second part of the review, the possibilities of one of the myotropic antispasmodics, mebeverine hydrochloride, in the treatment of IBS are considered in detail.

Structural and functional intestinal barrier abnormalities and chronic kidney disease. literature review. part ii

Abstract: The last few decades have been marked by significant progress in the investigation of the intestinal microbial-tissue complex and its role in the pathogenesis of a wide range of diseases. The presence of intestinal barrier dysfunction has also been confirmed in various nephropathies. Patients with chronic kidney disease (CKD) are characterized by specific alterations of the qualitative and quantitative composition of the gut microbiota. These changes contribute to an increase in the fermentation of food proteins into uremic toxins, such as p-cresyl sulfate, indoxyl sulfate and trimethylaminoxide, disorders of immune tolerance mechanisms of the mucous membrane, disorganization of intestinal epithelium tight junctions, which inevitably leads to an increase of transepithelial permeability. Translocation of bacteria and microbial metabolism products from the intestinal lumen into the systemic circulation is responsible for systemic inflammation, which is currently considered as one of the leading causes of the CKD progression and related complications. However, the exact mechanisms of gut-kidney interaction remain poorly understood. The second part of the review gives a detailed description of the structural and functional disorders of the intestinal muco-epithelial barrier identified in various nephropathies. The mechanisms of uremia-induced intestinal epithelial disruption are discussed, as well as the current therapeutic strategies that may attenuate consequences of intestinal barrier dysfunction in patients with CKD.